101
|
Fujii M, Tsunoda N, Hattori M, Murata T, Akahane K, Kamei K, Goto Y, Amemiya T, Nishimae K, Kubota T, Ito Y, Kurumiya Y, Yoshihara M, Nakanishi K, Kikumori T, Ando M, Nagino M. The efficacy of eribulin mesylate with trastuzumab for locally advanced or metastatic HER2-positive breast cancer treated with prior pertuzumab and/or T-DM1: Results from a phase II, single arm, multicenter study (N-SOG 10 study). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx654.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
102
|
Kobayashi A, Horinouchi H, Ito Y, Oe Y, Uchida S, Asakura K, Yoshida Y, Nakagawa K, Watanabe S. PS01.06 Feasibility of Salvage Pulmonary Resection after Definitive Chemoradiotherapy for Advanced Non-Small Cell Lung Cancer Patients. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
103
|
Yap YS, Ito Y, Bornstein O, Han Y, Samant T, Liu X, Chiu J. Phase Ib study of ribociclib (RIB) + letrozole (LET) in a subset of Asian patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx654.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
104
|
Itani H, Iwamoto K, Ito Y, Sasano H, Kondo S, Tanigawa M. P3.01-064 Detection of EGFR Mutations in Circulating Tumor DNA Using Plasma Samples: Clinical Validation of Cobas EGFR Mutation Test V2. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
105
|
Hayakawa M, Kajimoto K, Sugiu K, Yoshimura S, Hishikawa T, Yamagami H, Sakai N, Iihara K, Ogasawara K, Oishi H, Ito Y, Matsumaru Y. Prediction of intracranial hemorrhage after carotid artery stenting using preprocedural single-photon emission computed tomography. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
106
|
Ito Y, Mitsufuji T, Asano Y, Shimazu T, Kato Y, Tanahashi N, Maruki Y, Sakai F, Yamamoto T, Araki N. Naratriptan in the prophylactic treatment of cluster headache - a multicenter cooperative study -. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
107
|
Kono Y, Nisioka K, Komatuzaki Y, Ito Y, Li Y, Yoshino H, Tanaka R, Hattori N, Iguchi Y. CADASIL type 2 in two families prsenting mimic symptoms of CARASIL. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
108
|
Nishida S, Inagaki R, Furukawa S, Iwata M, Suzuki J, Ito Y, Yasuda T. Selegiline hydrochloride (SEL) inhibits the uptake of 3 meta–iodobenzylguanidine (MIBG) and influences the result of MIBG myocardial scintigraphy in patients with parkinsonism. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
109
|
Suzuki J, Inagaki R, Furukawa S, Iwata M, Nakai N, Nishida S, Ito Y. Efficacy of prehospital stroke scale including atrial fibrillation (Topspin) –10 years experiences. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
110
|
Yamakawa M, Hashimoto Y, Sakamoto T, Yamamoto F, Ito Y, Tajiri S, Watari M, Nakajima M, Ando Y. Clinical features of patients presenting reversible cerebral vasoconstriction without thunderclap headache. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
111
|
Horimoto Y, Hayashi E, Ito Y, Iida A, Hibino H, Inagaki A, Tajima T, Fukagawa K, Okita K, Yasui K, Nanbu I, Anan C, Uematsu N, Katada E, Matsukawa N, Kabasawa H. Dopaminergic performances in patients with parkinsonism — A combination study of dopamine transporter SPECT, dopamine synthesis and receptor pet. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
112
|
Tanaka C, Kanda M, Misawa K, Ito S, Ito Y, Mochizuki Y, Ishigure K, Yaguchi T, Teramoto J, Nakayama H, Kawase Y, Fujiwara M, Kodera Y. Nutritional recovery after open and laparoscopic distal gastrectomy for early gastric cancer: A prospective multicenter comparative trial (CCOG1204). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
113
|
Kawaguchi H, Aogi K, Masuda N, Nakayama T, Ito Y, Ohtani S, Sato N, Takano T, Saji S, Tokunaga E, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced/metastatic breast cancer (JBCRG-C06; Safari): A subgroup analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
114
|
Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka T, Morita S, Ohno S, Toi M. Neoadjuvant therapy with trastuzumab emtansine and pertuzumab in patients with HER2-positive primary breast cancer (A randomized, phase 2 study; JBCRG-20). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
115
|
Moriyama H, Asaoka Y, Ito Y. Kinetics of Tritium Recovery from Liquid Lithium by Molten Salt Extraction. ACTA ACUST UNITED AC 2017. [DOI: 10.13182/fst91-a29481] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
116
|
Sugidachi A, Ohno K, Jakubowski JA, Ito Y, Tomizawa A, Mizuno M. Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E-Deficient Mice. TH OPEN 2017; 1:e92-e100. [PMID: 31249914 PMCID: PMC6524843 DOI: 10.1055/s-0037-1605361] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Patients with acute coronary syndrome with diabetes mellitus (DM) exhibit an impaired platelet inhibitory response to clopidogrel which is only partially understood. DM was induced by the administration of streptozotocin (STZ) to 9-week-old mice. The antithrombotic effects of clopidogrel (10 mg/kg/d, orally × 5 days) were determined using a FeCl
3
-induced thrombosis model employing wild-type (WT), apolipoprotein E (apoE)-deficient, and diabetic apoE-deficient mice at 21 weeks. Antiplatelet effects were determined using flow cytometry. The antithrombotic effects of clopidogrel were similar in WT and apoE-deficient mice but were attenuated in diabetic apoE-deficient mice with the percent inhibition of thrombus area (µm
2
) by clopidogrel being 85.5% (WT mice), 75.0% (apoE-deficient mice), and 1.9% (diabetic apoE-deficient mice). The time to first occlusion and lumen stenosis also reflected a significant loss of the antithrombotic effects of clopidogrel in diabetic apoE-deficient mice. Ex vivo platelet activation, which was assessed using ADP-induced expression of activated glycoprotein IIb/IIIa, was completely inhibited by clopidogrel in these three groups of mice. In contrast, the effect of clopidogrel on the ex vivo expression of platelet P-selectin induced by protease-activated receptor 4–activating peptide was diminished in diabetic apoE-deficient mice compared with that in WT and apoE-deficient mice. These data suggest that diabetic apoE-deficient mice may serve as a useful model to better understand the impaired responses to clopidogrel in patients with DM, which may partially reflect a reduction of the effect of clopidogrel on thrombin-induced platelet activation.
Collapse
|
117
|
Tsutsumi M, Ito Y, Hirano K, Yamawaki M, Araki M, Kobayashi N, Sakamoto Y, Mori S, Takama T, Honda Y, Tokuda T, Makino K, Shirai S. P5188Long-term clinical outcomes after polymer-free paclitaxel-coated stent implantation for femoropopliteal disease in comparison with bare metal stent. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
118
|
Maejima Y, Ito Y, Tamura N, Konishi M, Isobe M. P681Blood coagulation factor Xa promotes the progression of atherosclerosis by enhancing inflammasome formation as a consequence of PAR2-mediated autophagy inhibition. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
119
|
Makino K, Hirano K, Yamawaki M, Araki M, Kobayashi N, Mori S, Sakamoto Y, Tsutsumi M, Takama T, Honda Y, Takahiro T, Shirai S, Ito Y. P5202The effectiveness of ultrasound-guided tibial artery endovascular interventions for chronic total occlusion lesions in critical limb ischemia. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
120
|
Kobayashi N, Hirano K, Yamawaki M, Araki M, Sakamoto Y, Mori S, Tsutsumi M, Honda Y, Tokuda T, Makino K, Shirai S, Ito Y. P5215Severity of angiographic dissection and future restenosis after balloon angioplasty for femoropopliteal disease. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
121
|
Suzuki M, Yoshimura H, Ito Y, Kanamori M. CORRELATIONS OF NURSING PRACTICES FOR ELDERLY WITH COGNITIVE IMPAIRMENT AND COMPETENCE IN HOSPITALS. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
122
|
Eid N, Ito Y, Futaki S, Kondo Y. Complete right- and left-sided thoracic ducts associated with aberrant left vertebral artery: unreported case with surgical implications. Folia Morphol (Warsz) 2017; 77:156-160. [PMID: 28653307 DOI: 10.5603/fm.a2017.0055] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Accepted: 05/21/2017] [Indexed: 11/25/2022]
Abstract
Anatomy is the keystone to an appropriate understanding of surgical and radiological sciences. Here the authors report on a rare case of complete right- and left-sided thoracic ducts (TDs) associated with aberrant left-vertebral artery (LVA) arising from the aortic arch. The TDs originated from right and left cisterna chyli and terminated separately close to the left venous angle. Superior to the aortic arch, the TDs showed different relationships to the LVA; the right TD was ventral, while the left was dorsal in position. This report is associated with other variations detailed below, and may have important implications in cervicothoracic surgery. (Folia Morphol 2018; 77, 1: 156-160).
Collapse
|
123
|
Aidala C, Ajitanand N, Akiba Y, Akimoto R, Alexander J, Alfred M, Aoki K, Apadula N, Asano H, Atomssa E, Awes T, Ayuso C, Azmoun B, Babintsev V, Bagoly A, Bai M, Bai X, Bannier B, Barish K, Bathe S, Baublis V, Baumann C, Baumgart S, Bazilevsky A, Beaumier M, Belmont R, Berdnikov A, Berdnikov Y, Black D, Blau D, Boer M, Bok J, Boyle K, Brooks M, Bryslawskyj J, Buesching H, Bumazhnov V, Butler C, Butsyk S, Campbell S, Canoa Roman V, Chen CH, Chi C, Chiu M, Choi I, Choi J, Choi S, Christiansen P, Chujo T, Cianciolo V, Cole B, Connors M, Cronin N, Crossette N, Csanád M, Csörgő T, Danley T, Datta A, Daugherity M, David G, DeBlasio K, Dehmelt K, Denisov A, Deshpande A, Desmond E, Ding L, Do J, D’Orazio L, Drapier O, Drees A, Drees K, Dumancic M, Durham J, Durum A, Elder T, Engelmore T, Enokizono A, Esumi S, Eyser K, Fadem B, Fan W, Feege N, Fields D, Finger M, Finger M, Fleuret F, Fokin S, Frantz J, Franz A, Frawley A, Fukao Y, Fukuda Y, Fusayasu T, Gainey K, Gal C, Garg P, Garishvili A, Garishvili I, Ge H, Giordano F, Glenn A, Gong X, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene S, Grosse Perdekamp M, Gu Y, Gunji T, Guragain H, Hachiya T, Haggerty J, Hahn K, Hamagaki H, Han S, Hanks J, Hasegawa S, Haseler T, Hashimoto K, Hayano R, He X, Hemmick T, Hester T, Hill J, Hill K, Hollis R, Homma K, Hong B, Hoshino T, Hotvedt N, Huang J, Huang S, Ichihara T, Ikeda Y, Imai K, Imazu Y, Imrek J, Inaba M, Iordanova A, Isenhower D, Isinhue A, Ito Y, Ivanishchev D, Jacak B, Jeon S, Jezghani M, Ji Z, Jia J, Jiang X, Johnson B, Joo K, Jorjadze V, Jouan D, Jumper D, Kamin J, Kanda S, Kang B, Kang J, Kang J, Kapukchyan D, Kapustinsky J, Karthas S, Kawall D, Kazantsev A, Key J, Khachatryan V, Khandai P, Khanzadeev A, Kijima K, Kim C, Kim D, Kim EJ, Kim M, Kim M, Kim YJ, Kim Y, Kincses D, Kistenev E, Klatsky J, Kleinjan D, Kline P, Koblesky T, Kofarago M, Komkov B, Koster J, Kotchetkov D, Kotov D, Krizek F, Kudo S, Kurita K, Kurosawa M, Kwon Y, Lacey R, Lai Y, Lajoie J, Lallow E, Lebedev A, Lee D, Lee G, Lee J, Lee K, Lee K, Lee S, Leitch M, Leitgab M, Leung Y, Lewis B, Lewis N, Li X, Li X, Lim S, Liu L, Liu M, Loggins VR, Lokos S, Lynch D, Maguire C, Majoros T, Makdisi Y, Makek M, Malaev M, Manion A, Manko V, Mannel E, Masuda H, McCumber M, McGaughey P, McGlinchey D, McKinney C, Meles A, Mendoza M, Meredith B, Metzger W, Miake Y, Mibe T, Mignerey A, Mihalik D, Milov A, Mishra D, Mitchell J, Mitsuka G, Miyasaka S, Mizuno S, Mohanty A, Mohapatra S, Moon T, Morrison D, Morrow S, Moskowitz M, Moukhanova T, Murakami T, Murata J, Mwai A, Nagae T, Nagai K, Nagamiya S, Nagashima K, Nagashima T, Nagle J, Nagy M, Nakagawa I, Nakagomi H, Nakamiya Y, Nakamura K, Nakamura T, Nakano K, Nattrass C, Netrakanti P, Nihashi M, Niida T, Nouicer R, Novák T, Novitzky N, Novotny R, Nyanin A, O’Brien E, Ogilvie C, Oide H, Okada K, Orjuela Koop J, Osborn J, Oskarsson A, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park I, Park J, Park S, Park S, Pate S, Patel L, Patel M, Peng JC, Peng W, Perepelitsa D, Perera G, Peressounko D, PerezLara C, Perry J, Petti R, Phipps M, Pinkenburg C, Pisani R, Pun A, Purschke M, Qu H, Radzevich P, Rak J, Ravinovich I, Read K, Reynolds D, Riabov V, Riabov Y, Richardson E, Richford D, Rinn T, Riveli N, Roach D, Rolnick S, Rosati M, Rowan Z, Runchey J, Ryu M, Sahlmueller B, Saito N, Sakaguchi T, Sako H, Samsonov V, Sarsour M, Sato K, Sato S, Sawada S, Schaefer B, Schmoll B, Sedgwick K, Seele J, Seidl R, Sekiguchi Y, Sen A, Seto R, Sett P, Sexton A, Sharma D, Shaver A, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva C, Silvermyr D, Singh B, Singh C, Singh V, Skoby M, Skolnik M, Slunečka M, Smith K, Solano S, Soltz R, Sondheim W, Sorensen S, Sourikova I, Stankus P, Steinberg P, Stenlund E, Stepanov M, Ster A, Stoll S, Stone M, Sugitate T, Sukhanov A, Sun J, Syed S, Takahara A, Takeda A, Taketani A, Tanaka Y, Tanida K, Tannenbaum M, Tarafdar S, Taranenko A, Tarnai G, Tennant E, Tieulent R, Timilsina A, Todoroki T, Tomášek M, Torii H, Towell C, Towell R, Tserruya I, Ueda Y, Ujvari B, van Hecke H, Vargyas M, Vazquez-Carson S, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vrba V, Vznuzdaev E, Wang X, Wang Z, Watanabe D, Watanabe K, Watanabe Y, Watanabe Y, Wei F, Whitaker S, Wolin S, Wong C, Woody C, Wysocki M, Xia B, Xu C, Xu Q, Yamaguchi Y, Yanovich A, Yin P, Yokkaichi S, Yoo J, Yoon I, You Z, Younus I, Yu H, Yushmanov I, Zajc W, Zelenski A, Zharko S, Zhou S, Zou L. Cross section and transverse single-spin asymmetry of muons from open heavy-flavor decays in polarized
p+p
collisions at
s=200 GeV. Int J Clin Exp Med 2017. [DOI: 10.1103/physrevd.95.112001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
124
|
Mizobuchi M, Ito Y, Tanaka M, Funatsu A, Kobayashi T, Nakamura S. P1392Effects of minimally interrupted direct oral anticoagulants on the intensity of anticoagulation during atrial fibrillation ablation; A single-center retrospective study. Europace 2017. [DOI: 10.1093/ehjci/eux158.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
125
|
Ito Y, Igarashi M, Igawa M, Nogami A, Aonuma K. P1695Atrial stunning was frequently observed just after electrical cardioversion in the patients with atrial fibrillation: who is more susceptible? Europace 2017. [DOI: 10.1093/ehjci/eux161.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
126
|
Ito Y, Ambe K, Kobayashi M, Tohkin M. Ethnic Difference in the Pharmacodynamics-efficacy Relationship of Dipeptidyl Peptidase-4 Inhibitors Between Japanese and non-Japanese Patients: A Systematic Review. Clin Pharmacol Ther 2017; 102:701-708. [PMID: 28378919 DOI: 10.1002/cpt.692] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Revised: 02/16/2017] [Accepted: 03/14/2017] [Indexed: 12/29/2022]
Abstract
A systematic review of the differences in the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors between Japanese and non-Japanese subjects was conducted. We searched for randomized controlled trials in patients with type 2 diabetes mellitus (T2DM) that studied the intervention of a DPP-4 inhibitor once-daily vs. placebo, as monotherapy or as add-on therapy. Data regarding placebo-corrected HbA1c reduction and trough DPP-4 inhibition rate after ≥12 weeks' treatment were extracted. In the 12 eligible studies, linear regression analysis revealed that the hemoglobin A1c (HbA1c) reduction at each DPP-4 inhibition level was larger in studies involving Japanese patients than in studies involving non-Japanese patients, with statistical significance between the two groups (P < 0.0001). Sensitivity analysis excluding studies of add-on therapies supported the robustness of the result. Our study indicated that DPP-4 inhibitors show greater efficacy in Japanese patients than in non-Japanese patients, which may be an important consideration in the global development strategy of new diabetic medications.
Collapse
|
127
|
Nozaki M, Kagami Y, Shibata T, Nakamura K, Ito Y, Nishimura Y, Kawaguchi Y, Saito Y, Nagata Y, Matsumoto Y, Akimoto T, Nishimura T, Uno T, Tsujino K, Kataoka M, Kodaira T, Shiraishi K, Inoue K, Isohashi F, Hiraoka M, Karasawa K, Izumi S, Sakurai H. EP-1156: A clinical trial on hypofractionated whole breast irradiation after breast-conserving surgery. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31592-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
128
|
Inoue T, Ito Y, Nishihira M, Araki O, Karube Y, Maeda S, Kobayashi S, Ikeda N, Inoue H, Tamura M, Matsumura Y, Chida M. [Salvage Surgery Following Chemoradiotherapy for Thymic Basaloid Cell Carcinoma]. KYOBU GEKA. THE JAPANESE JOURNAL OF THORACIC SURGERY 2017; 70:352-355. [PMID: 28496081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
We performed salvage surgery after chemoradiotherapy(CRT) in a patient with thymic basaloid cell carcinoma. A 46-year-old man with an abnormal chest shadow on X-ray findings was referred to our hospital. Computed tomography revealed a partially solid tumor along with a multilocular cyst in the anterior mediastinum with mediastinal lymph node swelling infiltrating to the superior vena cava(SVC). Positron emission tomography revealed FDG accumulation (SUVmax 7.94)in the tumor. Pathological findings of a tumor biopsy specimen obtained by thoracoscopy led to a diagnosis of thymic basaloid cell carcinoma. Following CRT (ADOC+RT:60 Gy), a complete resection (R0)with replacement of the SVC was performed. The postoperative course was uneventful, and the patient was alive at 20 months after surgery with metastasis to the cervical lymph nodes and bone.
Collapse
|
129
|
Tokuzawa T, Kawahata K, Nagayama Y, Inagaki S, De Vries PC, Mase A, Kogi Y, Yokota Y, Hojo H, Tanaka K, Ejiri A, Pavlichenko RO, Yamaguchi S, Yoshinaga T, Kuwahara D, Shi Z, Tsuchiya H, Ito Y, Hirokura S, Sudo S, Komori A. Developments of Electron Cyclotron Emission Spectroscopy and Microwave Reflectometry on LHD. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst10-a10822] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
130
|
Akiyama T, Kawahata K, Tanaka K, Tokuzawa T, Ito Y, Okajima S, Nakayama K, Michael CA, Vyacheslavov LN, Sanin A, Tsuji-Iio S. Interferometer Systems on LHD. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst10-8] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
131
|
Wakai E, Kondo H, Kanemura T, Furukawa T, Hirakawa Y, Watanabe K, Ida M, Ito Y, Niitsuma S, Edao Y, Fujishiro K, Nakaniwa K, Hoashi E, Horiike H, Serizawa H, Kawahito Y, Fukada S, Sugie Y, Suzuki A, Yagi J, Tsuji Y, Furuya K, Groeschel F, KNASTER J, MICCHICHE G, IBARRA A, HEIDINGER R, NITTI F, SUGIMOTO M. Engineering Validation and Engineering Design of Lithium Target Facility in IFMIF/EVEDA Project. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst13-770] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
132
|
Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur J Surg Oncol 2017; 44:307-315. [PMID: 28343733 DOI: 10.1016/j.ejso.2017.03.004] [Citation(s) in RCA: 187] [Impact Index Per Article: 26.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 12/01/2016] [Accepted: 03/09/2017] [Indexed: 12/15/2022] Open
Abstract
Papillary microcarcinoma (PMC) of the thyroid is defined as papillary thyroid carcinoma (PTC) measuring ≤1 cm. Many autopsy studies on subjects who died of non-thyroidal diseases reported latent small thyroid carcinoma in up to 5.2% of the subjects. A mass screening study for thyroid cancer in Japanese adult women detected small thyroid cancer in 3.5% of the examinees. This incidence was close to the incidence of latent thyroid cancer and more than 1000 times the prevalence of clinical thyroid cancer in Japanese women reported at that time. The question of whether it was correct to treat such PMCs surgically then arose. In 1993, according to Dr. Miyauchi's proposal, Kuma Hospital initiated an active surveillance trial for low-risk PMC as defined in the text. In 1995, Cancer Institute Hospital in Tokyo, Japan, started a similar observation trial. The accumulated data from the trials at these two institutions strongly suggest that active surveillance (i.e., observation without immediate surgery) can be the first-line management for low-risk PMC. Although our data showed that young age and pregnancy might be risk factors of disease progression, we think that these patients can also be candidates for active surveillance, because all of the patients who showed progression signs were treated successfully with a rescue surgery, and none of them died of PTC. In this review, we summarize the data regarding the active surveillance of low-risk PMC as support for physicians and institutions that are considering adopting this strategy.
Collapse
|
133
|
Fukada I, Ito Y, Kobayashi K, Shibayama T, Miyamoto K, Takahashi S, Horii R, Akiyama F, Iwase T, Ohno S. Predictive factors and value of ypN+ after neoadjuvant chemotherapy in clinically lymph node-negative breast cancer. Breast 2017. [DOI: 10.1016/s0960-9776(17)30296-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
134
|
Ogiya A, Iwase T, Miyagi Y, Oguchi M, Ito Y, Horii R, Akiyama F, Ohno S. Treatment outcomes of stage IIIC breast cancer: a single institutional review. Breast 2017. [DOI: 10.1016/s0960-9776(17)30229-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
135
|
Araki K, Fukada I, Kobayashi K, Takahashi S, Ito Y. Abstract P5-15-11: Eribulin should be a candidate strategy in combination with pertuzumab plus trastuzumab for taxane pretreated HER2 positive advance breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-15-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Pertuzumab (P) improves clinical outcome when combined with docetaxel and trastuzumab (T). The efficacy of continuing multiple anti-HER2 therapy including P and/or T after initial progression is unclear. Eribulin mesylate (ERI) is able to overcome taxane (TAX) resistance advanced breast cancer (ABC). The objective of this study is to investigate the efficacy and safety of ERI plus P and T for both TAX and T pretreated HER2-positive ABC. Methods: This is a single institute, open-label, single-arm, Phase II study with pharmacokinetics (PK) of ERI (UMIN000012375). The initial dose of P is 840 mg, followed by 420 mg q3w; the initial dose of T 8 mg/kg, followed by 6 mg/kg q3w; ERI is administered at 1.4 mg on Days 1 and 8 of each cycle, q3w. Dose reductions of ERI (to 1.1 and 0.7 mg/m2) were permitted to manage any toxicity (more than grade 3). Patients (Pts) must have previous treatment with both TAX and T. The primary endpoint is assessed overall response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), safety, and PK of ERI. Left ventricular ejection function (LVEF) was evaluated before and end of this study. Results: Thirty Pts were enrolled. Median age at baseline was 57 years. Half of Pts had endocrine positive. All Pts were treated with TAX and T. Twenty-one Pts were treated with anthracycline-based treatment (70%). Median number of previous chemotherapy was 4 (2-5). Pts had multiple metastases, 40% with bone, 36.7% with lung, 20% with liver, and 10% with brain. Pts received a median number of 8 cycles of ERI (mean dose 1.2 ± 0.19 mg/sqm), 8 cycles of both P and T. Total number of 27 Pts needed to reduce dose of ERI because of adverse events (AEs) especially grade 3 neutropenia. The ORR (CR+PR) was 34.8% (95% CI 16.4-57.3, n=23) with median PFS of 42.6 weeks (95% CI 20.3-51.9, n=30). Clinical benefit rate (CR+PR+≥6 month SD) was 60.9% (95% CI 16.4-57.3%). T-DM1 pretreated affected poor outcome than the other factors (p=0.0011). The most common grade 3/4 AEs were neutropenia in 20 Pts (66.7%) without febrile neutropenia. Grade 1/2 AEs were fatigue in 24 Pts (80%), anorexia in 23 Pts (76.7%), anemia in 22 Pts (73.3%), diarrhea in 20 Pts (66.7%), peripheral neuropathy in 16 Pts (53.3%), and hand-foot syndrome in 12 Pts (43.3%). Baseline LVEF was 67%. One Pt had asymptomatic LVEF decrease (below an absolute value of 55%). Otherwise, there was no overall decrease in mean LVEF from baseline. Nine points (pre-dose, end of infusion, 0.5, 1, 2, 4, 24, 72, and 168 h after ERI) of PK analyses were evaluated in 6 Pts, and 3 point (pre-dose, end of infusion, and 168 h after ERI) in 10 Pts. PK parameters of ERI were as follows; Maximum plasma concentration (Cmax) was 375.96 (257.6-531.8) ng/ml, terminal half-life was 36.807 (31.90-40.80) h, total clearance was 1.945 (1.15-3.15) L/h/m2. Cmax of ERI was not correlated with neutrophil count (R2=0.2338, n=16). Conclusions: The combination of ERI plus P and T was well tolerated; no new safety signals ware observed. PK parameter of ERI were as same as previous reports when combined with both P and T. ERI might be a one of strategy in combination with P plus T for TAX pretreated HER2 positive ABC.
Citation Format: Araki K, Fukada I, Kobayashi K, Takahashi S, Ito Y. Eribulin should be a candidate strategy in combination with pertuzumab plus trastuzumab for taxane pretreated HER2 positive advance breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-15-11.
Collapse
|
136
|
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. Abstract P4-21-14: A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.Background: In patients with HER2-positive metastatic breast cancer (MBC) who progressed on trastuzumab (H)-based therapy, both continuing H beyond progression and switching to lapatinib (L) in combination with chemotherapy are valid options. However, it is unclear which strategy is more effective and how we can select a proper strategy in each patient.
Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of H + capecitabine (X) (HX) or L + X (LX) in women with HER2-positive MBC who were previously treated with taxanes and progressed on H-containing regimens. Patients treated with more than two chemotherapy regimens for MBC were excluded. Those treated with pertuzumab and/or T-DM1 were allowed to enroll in this study. Patients with brain metastases were also included if they are asymptomatic. Patients received H (4mg/kg loading then 2mg/kg weekly or 8mg/kg loading then 6mg/kg every 3 weeks) and X (2500 mg/m2/day on days 1-14 every 3weeks) in HX arm and L (1250 mg/day) and X (2000 mg/m2/day on days 1-14 every 3weeks) in LX arm until progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), objective response rate (ORR), proportion of subjects progressing with brain metastases as site of first progression, and safety.We also assessed biomarkers in tumor tissues and circulating cell-free DNA.
Results: Between May 2011 and December 2014, 86 patients (43 in HX arm and 43 in LX arm) were enrolled in this study. Median age was 58 years (range 34-81), ECOG performance status was 0 (63%), 1 (35%), or 2 (2%), 63% had hormone receptor-positive disease, 15% had brain metastases, 56% had relapsed after primary surgery, and 23% had received adjuvant or neo-adjuvant trastuzumab. Median follow-up time was 44.6 months. Median PFS was 6.1 months in HX arm and 7.1 months in LX arm (hazard ratio 0.81 90% CI 0.55-1.21; p=0.39), median OS was 31.0 months in HX arm and not reached in LX arm (hazard ratio 0.58 95% CI 0.26-1.31; p=0.18), ORR was 40% in HX arm and 41% in LX arm (p=1.00), disease control rate was 73% in HX arm and 92% in LX arm (p=0.038), and proportion of subjects progressing with brain metastases as site of first progression was 5% in HX arm and 5% in LX arm. Grade 3-4 toxicities included hand-foot syndrome (21% in HX arm and 21% in LX arm) and diarrhea (9% in HX arm and 16% in LX arm). In subgroup analyses, PFS benefit in LX arm compared to HX arm was significantly larger among patients who had received previous systemic treatment for metastatic disease for less than 1 year (interaction p=0.007). Subgroup analyses by biomarkers will be presented at the meeting.
Conclusions: In women with HER2-positive MBC previously treated with trastuzumab and taxanes, lapatinib + capecitabine tended to yield better PFS and OS than trastuzumab beyond progression + capecitabine, although they were not statistically significant.
Citation Format: Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-14.
Collapse
|
137
|
Tsurutani J, Sakai K, Takao T, Kimura H, Kawabata H, Tanaka K, Takahashi M, Ito Y, Takao S, Aogi K, Sato K, Tsuji Y, Yamanaka T, Nakanishi Y, Saeki T, Nishio K. Abstract P2-05-24: Prognostic value of circulating PIK3CA mutations revealed with digital PCR in patients with HER2-positive advanced breast cancer: Results of West Japan Oncology Group study 6110BTR. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
|
138
|
You D, Fukuzawa H, Sakakibara Y, Takanashi T, Ito Y, Maliyar GG, Motomura K, Nagaya K, Nishiyama T, Asa K, Sato Y, Saito N, Oura M, Schöffler M, Kastirke G, Hergenhahn U, Stumpf V, Gokhberg K, Kuleff AI, Cederbaum LS, Ueda K. Charge transfer to ground-state ions produces free electrons. Nat Commun 2017; 8:14277. [PMID: 28134238 PMCID: PMC5290264 DOI: 10.1038/ncomms14277] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Accepted: 12/09/2016] [Indexed: 11/09/2022] Open
Abstract
Inner-shell ionization of an isolated atom typically leads to Auger decay. In an environment, for example, a liquid or a van der Waals bonded system, this process will be modified, and becomes part of a complex cascade of relaxation steps. Understanding these steps is important, as they determine the production of slow electrons and singly charged radicals, the most abundant products in radiation chemistry. In this communication, we present experimental evidence for a so-far unobserved, but potentially very important step in such relaxation cascades: Multiply charged ionic states after Auger decay may partially be neutralized by electron transfer, simultaneously evoking the creation of a low-energy free electron (electron transfer-mediated decay). This process is effective even after Auger decay into the dicationic ground state. In our experiment, we observe the decay of Ne2+ produced after Ne 1s photoionization in Ne-Kr mixed clusters.
Collapse
|
139
|
Selvarajan V, Osato M, Nah GSS, Yan J, Chung TH, Voon DCC, Ito Y, Ham MF, Salto-Tellez M, Shimizu N, Choo SN, Fan S, Chng WJ, Ng SB. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC. Leukemia 2017; 31:2219-2227. [PMID: 28119527 PMCID: PMC5629367 DOI: 10.1038/leu.2017.40] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Revised: 01/03/2017] [Accepted: 01/10/2017] [Indexed: 12/14/2022]
Abstract
RUNX3, runt-domain transcription factor, is a master regulator of gene expression in major developmental pathways. It acts as a tumor suppressor in many cancers but is oncogenic in certain tumors. We observed upregulation of RUNX3 mRNA and protein expression in nasal-type extranodal natural killer (NK)/T-cell lymphoma (NKTL) patient samples and NKTL cell lines compared to normal NK cells. RUNX3 silenced NKTL cells showed increased apoptosis and reduced cell proliferation. Potential binding sites for MYC were identified in the RUNX3 enhancer region. Chromatin immunoprecipitation-quantitative PCR revealed binding activity between MYC and RUNX3. Co-transfection of the MYC expression vector with RUNX3 enhancer reporter plasmid resulted in activation of RUNX3 enhancer indicating that MYC positively regulates RUNX3 transcription in NKTL cell lines. Treatment with a small-molecule MYC inhibitor (JQ1) caused significant downregulation of MYC and RUNX3, leading to apoptosis in NKTL cells. The growth inhibition resulting from depletion of MYC by JQ1 was rescued by ectopic MYC expression. In summary, our study identified RUNX3 overexpression in NKTL with functional oncogenic properties. We further delineate that MYC may be an important upstream driver of RUNX3 upregulation and since MYC is upregulated in NKTL, further study on the employment of MYC inhibition as a therapeutic strategy is warranted.
Collapse
|
140
|
Tasaki M, Saito K, Nakagawa Y, Imai N, Ito Y, Aoki T, Kamimura M, Narita I, Tomita Y, Takahashi K. Acquired Downregulation of Donor-Specific Antibody Production After ABO-Incompatible Kidney Transplantation. Am J Transplant 2017; 17:115-128. [PMID: 27343838 DOI: 10.1111/ajt.13937] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Revised: 05/31/2016] [Accepted: 06/21/2016] [Indexed: 01/25/2023]
Abstract
The mechanism of long-term B cell immunity against donor blood group antigens in recipients who undergo ABO-incompatible (ABOi) living-donor kidney transplantation (LKTx) is unknown. To address this question, we evaluated serial anti-A and anti-B antibody titers in 50 adult recipients. Donor-specific antibody titers remained low (≤1:4) in 42 recipients (84%). However, antibodies against nondonor blood group antigens were continuously produced in recipients with blood type O. We stimulated recipients' peripheral blood mononuclear cells in vitro to investigate whether B cells produced antibodies against donor blood group antigens in the absence of graft adsorption in vivo. Antibodies in cell culture supernatant were measured using specific enzyme-linked immunosorbent assays (ELISAs). Thirty-five healthy volunteers and 57 recipients who underwent ABO-compatible LKTx served as controls. Antibody production in vitro against donor blood group antigens by cells from ABOi LKTx patients was lower than in the control groups. Immunoglobulin deposits were undetectable in biopsies of grafts of eight recipients with low antibody titers (≤1:4) after ABOi LKTx. One patient with blood type A1 who received a second ABOi LKTx from a type B donor did not produce B-specific antibodies. These findings suggest diminished donor-specific antibody production function in the setting of adult ABOi LKTx.
Collapse
|
141
|
Suzuki I, Matsumoto A, Ito Y, Yamada Y. Novel fast-sintered zirconia for chair-side dentistry. Dent Mater 2017. [DOI: 10.1016/j.dental.2017.08.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
142
|
Takayama K, Ito Y, Kaneko H, Kataoka K, Sugita T, Maruko R, Hattori K, Ra E, Haga F, Terasaki H. Comparison of indocyanine green angiography and optical coherence tomographic angiography in polypoidal choroidal vasculopathy. Eye (Lond) 2017; 31:45-52. [PMID: 27813526 PMCID: PMC5233943 DOI: 10.1038/eye.2016.232] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 09/14/2016] [Indexed: 11/08/2022] Open
Abstract
PurposeTo compare optical coherence tomographic angiography (OCTA) and indocyanine green angiography (ICGA) images for detecting polypoidal lesions (PLs) and branching vascular networks (BVNs), and to measure the polypoidal areas (PAs) in patients with polypoidal choroidal vasculopathy (PCV).MethodsAll patients underwent ICGA, optical coherence tomography (OCT), and OCTA. We compared the detection sensitivity for PL and BVN, as evaluated by the ICGA and OCTA images. Furthermore, PA measured by ICGA was divided into two groups: one in which the area could be measured by OCTA (ICGA+OCTA+) and the other in which the area could not be measured by OCTA (ICGA+OCTA-).ResultsTwenty-one consecutive eyes of 21 patients (mean age, 73.8±9.8 years) were included. ICGA detected PL in all eyes (100%), whereas OCTA detected PL in 16 eyes (75.2%); ICGA detected BVN in 15 eyes (71.4%), whereas OCTA detected BVN in 20 eyes (95.2%). The mean PA in ICGA+OCTA+ and ICGA+OCTA- was 0.24±0.04 and 0.14±0.01 mm2, respectively; a significant difference was observed between ICGA+OCTA+ PA and ICGA+OCTA- PA (P<0.0001). In addition, the mean PA in the ICGA+OCTA+ group measured by ICGA and OCTA was 0.24±0.04 was 0.19±0.04 mm2, respectively; these values were significantly different (P=0.0046).ConclusionsOCTA might detect more BVNs and fewer PLs compared with ICGA, and PL detected by OCTA might be smaller than those detected by ICGA.
Collapse
|
143
|
Inoue T, Nakazato Y, Chida M, Ito Y, Nishihira M, Araki O, Karube Y, Maeda S, Kobayashi S. P2.01-080 Mitosis Count of Lung Adenocarcinomas: Correlation between the Phosphorylated Histone 3, Number of Cancer Cells, Nuclear Grade, and Prognosis. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.1132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
144
|
Wakai E, Kanemura T, Kondo H, Hirakawa Y, Ito Y, Serizawa H, Kawahito Y, Higashi T, Suzuki A, Fukada S, Furuya K, Esaki K, Yagi J, Tsuji Y, Ito T, Niitsuma S, Yoshihashi-Suzuki S, Watanabe K, Furukawa T, Groeschel F, Micciche G, Manorri S, Favuzza P, Nitti F, Heidinger R, Terai T, Horiike H, Sugimoto M, Ohira S, Knaster J. Engineering validation for lithium target facility of the IFMIF under IFMIF/EVEDA project. NUCLEAR MATERIALS AND ENERGY 2016. [DOI: 10.1016/j.nme.2016.05.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
145
|
Noura S, Ohue M, Hasegawa J, Hirota M, Matsumura T, Ito Y, Miyoshi N, Kobayashi H, Kotake K, Sugihara K. 177P New staging system for colorectal cancer patients with synchronous peritoneal metastasis in accordance with the Japanese Classification of Colorectal Carcinoma: A multi-institutional study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
146
|
Fukada I, Ito Y, Shibayama T, Kobayashi K, Teruya N, Takahashi S, Horii R, Akiyama F, Iwase T, Toi M, Ohno S. 89P Questionnaire survey on patients’ preference for orally disintegrating tablets or granules of S-1 in postoperative adjuvant treatment for breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw575.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
147
|
Noura S, Ohue M, Hasegawa J, Hirota M, Matsumura T, Ito Y, Miyoshi N, Kobayashi H, Kotake K, Sugihara K. 177P New staging system for colorectal cancer patients with synchronous peritoneal metastasis in accordance with the Japanese Classification of Colorectal Carcinoma: A multi-institutional study. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00335-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
148
|
Fukada I, Ito Y, Shibayama T, Kobayashi K, Teruya N, Takahashi S, Horii R, Akiyama F, Iwase T, Toi M, Ohno S. 89P Questionnaire survey on patients' preference for orally disintegrating tablets or granules of S-1 in postoperative adjuvant treatment for breast cancer. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00249-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
149
|
Qiu HJ, Chen LY, Ito Y, Kang JL, Guo XW, Liu P, Kashani H, Hirata A, Fujita T, Chen MW. An ultrahigh volumetric capacitance of squeezable three-dimensional bicontinuous nanoporous graphene. NANOSCALE 2016; 8:18551-18557. [PMID: 27782251 DOI: 10.1039/c5nr08852f] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Graphene with a large specific surface area and high conductivity has a large specific capacitance. However, its volumetric capacitance is usually very low because the restacking of 2D graphene sheets leads to the loss of the large ion-accessible surface area. Here we report squeezable bicontinuous nanoporous nitrogen-doped graphene, which is extremely flexible and can tolerate large volume contraction by mechanical compression without the face-to-face restacking occurring. The compressed nanoporous N-doped graphene with a large ion accessible surface area and high conductivity shows an ultrahigh volumetric capacitance of ∼300 F cm-3 together with excellent cycling stability and high rate performance.
Collapse
|
150
|
Fudeyasu K, Kawae T, Fukuhara K, Iwaki D, Nakashima Y, Ueda K, Ito Y, Hiramatsu A, Kimura H. The effect of liver dysfunction on muscle strength in liver disease patients. Physiotherapy 2016. [DOI: 10.1016/j.physio.2016.10.359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|